Clinical Trial Update: Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients [Phase 1, Phase 2]

View source ↗

Summary

An update on Phase 1 and Phase 2 trials evaluating ROSE-010 for improving gastrointestinal transit in patients with constipation-predominant irritable bowel syn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome Constipation Predominant

Drugs mentioned

• ROSE-010 (glucagon-like peptide-1 analogue)

Snippet

Sponsor: Mayo Clinic | Conditions: Irritable Bowel Syndrome Constipation Predominant | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-05-31